top of page


  1. Hecking M, Kainz A, Schillinger M, , Birsan T, Rasoul-Rockenschaub S, Böhmig GA, Schmaldienst S, Watschinger B, Hörl WH, Mühlbacher F, Säemann MD. Analysis of liver function in renal transplant recipients undergoing C2-monitoring for cyclosporine. Transpl Int. 2008 Mar;21(3):223-33.

  2. Posch C, Vesely M, Monshi B, Feichtinger H, Cziegler K, Rappersberger K. Animal-type melanoma - tumor cell invasion of dermal lymphatics and molecular identification of lymph node metastasis. J Dtsch Dermatol Ges. 2012 Jan;10(1):38-41.

  3. Posch C, Moslehi H, Feeney L, Green G, Ebaee A, Feichtenschlager V, Chong K, Peng L, Dimon M, Phillips T, Daud A, McCalmont T, LeBoit P, Ortiz-Urda S. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):4015-20.

  4. Weingast J, Scheibboeck C, Wurm EMT, Ranharter E, Porkert S, Dreiseitl S, , Binder M. A prospective study of mobile phones for dermatology in a clinical setting. J Telemed Telecare. 2013 Jun;19(4):213-8.

  5. Posch C, Pinney E, Ortiz-Urda S, Montes-Camacho M, Naughton GK. Human Multipotent Stem Cell Proteins Induce Apoptosis in Skin Cancer Cells. Journal of Cancer Therapy. 2013 July 4. doi:10.4236/jct.2013.46A1001

  6. Latorre A*, , Garcimartin J, Ortiz-Urda S, Somoza A. Single-Point Mutation Detection in RNA Extracts using Gold Nanoparticles Modified with Hydrophobic Molecular Beacons. . 2014 Mar 21;50(23):3018-20 (*authors contributed equally)

  7. Posch C, Weihsengruber F, Bartsch K, Feichtenschlager V, Sanlorenzo M, Vujic I, Monshi B, Ortiz-Urda S, Rappersberger K. Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients. Br J Cancer. 2014 Mar 18;110(6):1427-32

  8. Vujic I, Marker M, Mühlehner D, , Monshi B, Breier F, Steiner A, Rappersberger K. Merkel cell carcinoma: mitoses, expression of Ki-67 and bcl-2 correlate with disease progression. . 2015 Mar;29(3):542-8.

  9. Sanlorenzo M, Wehner MR, Linos E, Kornak J, Wolfgang K, , Vujic I, Johnston K, Gho D, Monico G, McGrath JT, Osella-Abate S, Quaglino P, Cleaver J E, Ortiz-Urda S. The Risk of Melanoma in Pilots and Cabin Crew - A Meta-analysis. JAMA Dermatol. 2015 Jan;151(1):51-8.

  10. Sanlorenzo M, Vujic I, , Cleaver JE, Quaglino P, Ortiz-Urda S. The Risk of Melanoma in Pilots and Cabin Crew: UV Measurements in Flying Airplanes. JAMA Dermatol. 2015 Apr;151(4):450-2.

  11. Latorre A*, , Garcimartin J, Zekhtser M, Ma J, Celli A, Rappersberger K, Ortiz-Urda S, Somoza A. DNA stabilized gold nanoparticles for targeted delivery of anticancer therapeutics. Nanoscale. 2014 Jul 7;6(13):7436-42 (*authors contributed equally)

  12. Monshi B, , Vuic I, Sesti A, Sobotka S, Rappersberger K. Efficacy of intravenous immunoglobulins in livedoid vasculopathy: long term-follow up of 11 patients. . 2014 Oct;71(4):738-44.

  13. Vujic I, , Sanlorenzo M, Yen A, Tsumura A, Kwong A, Feichtenschlager V, Rappersberger K, Ortiz-Urda S. Mutant NRAS Q61 shares signaling similarities across various cancer types - potential implications for future therapies. . 2014 Sep 15;5(17):7936-44.

  14. Posch C*, Latorre A*, Crosby MB, Celli A, Latorre A, Vujic I, Sanlorenzo M, Green GA, Weier J, Zekhtser M, Ma J, Monico G, Char DH, Jusufbegovic D, Rappersberger K, Somoza A, Ortiz-Urda S. Detection of GNAQ Mutations and Reduction of Cell Viability in Uveal Melanoma Cells with Functionalized Gold Nanoparticles. Biomed Microdevices. 2015 Feb;17(1):9908 (*authors contributed equally)

  15. Sanlorenzo M, Choudhry A, Vujic I, , Chong K, Johnston K, Meier M, Osella-Abate S, Quaglino P, Daud A, Algazi A, Rappersberger K, Ortiz-Urda S. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. . 2014 Dec;71(6):1102-1109

  16. Vujic I, Sanlorenzo M, , Esteve-Puig R, Yen AJ, Kwong A, Tsumura A, Murphy R, Rappersberger K, Ortiz-Urda S. Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer. Oncotarget. 2015 Jan 20;6(2):969-78.

  17. Posch C, Cholewa BD, Vujic I, Sanlorenzo M, Ma J, Kim ST, Kleffel S, Schatton T, Rappersberger K, Gutteridge R, Ahmad N, Ortiz-Urda S. Combined inhibition of MEK and Plk1 has synergistic anti-tumor activity in NRAS mutant melanoma. J Invest Dermatol. 2015 Oct;135(10):2475-83.

  18. Kleffel S, , Barthel SR, Mueller H, Schlapbach C, Guenova E, Elco CP, Lee N, Juneja VR, Zhan Q, Lian CG, Thomi R, Hoetzenecker W, Cozzio A, Dummer R, Mihm MC Jr, Flaherty KT, Frank MH, Murphy GF, Sharpe AH, Kupper TS, Schatton T. Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. . 2015 Sep 10;162(6):1242-56.

  19. Vujic I, Sanlorenzo M, Esteve-Puig R, Vujic M, Kwong A, Tsumura A, Murphy RM, Moy A, , Monshi B, Rappersberger K, Ortiz-Urda S. Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells. . 2016 Feb 9;7(6):7297-306.

  20. Kleffel S, Lee N, Lezcano C, Wilson B, Sobolewski K, Saab K, Mueller H, Zhan Q, , Elco C, DoRosario A, Garcia S, Thakuria M, Wang Y, Wang L, Murphy G, Frank M, Schatton T. ABCB5-targeted chemoresistance reversal inhibits Merkel cell carcinoma growth. . 2016 Apr;136(4):838-46.

  21. Monshi B, Vujic M, Kivaranovic D, Sesti A, Oberaigner W, Vujic I, Ortiz-Urda S, , Feichtinger H, Hackl M, Rappersberger K. The burden of malignant melanoma – Lessons to be learned from Austria. Eur J Cancer. 2016 Mar;56:45-53

  22. Vigl K*, , Richter L, Monshi B, Rappersberger K. Pyoderma gangrenosum during pregnancy – treatment options revisited. J Eur Acad Dermatol Venereol. 2016 Nov;30(11):1981-1984. (*authors contributed equally)

  23. Posch C, Vujic I, Sanlorenzo M, Monshi B, Weihsengruber F, Rappersberger K, Ortiz-Urda S. Searching for the chokehold of NRAS mutant melanoma. J Invest Dermatol. 2016 Jul;136(7):1330-6.

  24. Sanlorenzo M, Vujic I, Ma J, Lin K, Lai K, Lee D, Vujic M, Oses-Prieto JA, Chand S, Rodriguez-Peralto JL, Burlingame A, Ortiz-Urda S. Oncogenic KIT mutations in different exons lead to specific changes in melanocyte phospho-proteome. J Proteomics. 2016 Jul 20;144:140-7.

  25. Posch C, Sanlorenzo M, Vujic I, Oses-Prieto JA, Cholewa BD, Kim ST, Ma J, Lai K, Zekhtser M, Esteve-Puig R, Green G, Chand S, Panzer-Grümayer R, Burlingame AL, Rappersberger K, Ortiz-Urda S. Phospho-proteomic analysis reveals increased CK2a kinase activity in NRAS(Q61) mutant melanoma. J Invest Dermatol. 2016 Oct;136(10):2041-8.

  26. Posch C, Moslehi H, Sanlorenzo M, Green G, Vujic I, Panzer-Grümayer ER, Rappersberger K, Ortiz-Urda S. Imatinib and nilotinib block mutant c-KIT mediated migration of melanocytes and melanoma cells in vitro and in vivo. Oncotarget. 2016 Jul 19;7(29):45916-45925. 

  27. Sesti A, Rappersberger K, . Bullous Sweet’s syndrome with pulmonary involvement. . 2017 Aug;68(8):649-652

  28. Richter L, Vujic I, Sesti A, Monshi B, Sanlorenzo M, , Rappersberger K. Etanercept, adalimumab, and ustekinumab in psoriasis: analysis of 209 treatment series in Austria. J Dtsch Dermatol Ges. 2017 Mar;15(3):309-317.

  29. Posch C, Monshi B, Quint T, Vujic I, Lilgenau N, Rappersberger K. The role of wide local excision for the treatment of severe hidradenitis suppurativa (Hurley grade III) – retrospective analyses of 74 patients. J Am Acad Dermatol. 2017 Apr 1. pii: S0190-9622(17)30149-4. 

  30. Bal C, Rappersberger K, . Adverse events of subcutaneous, drug releasing implants for the treatment of opioid drug addiction. Accepted for publication at J Dtsch Dermatol Ges. 3/2017

  31. Álvarez-Rodríguez B, Latorre A, *, Somoza Á*. Recent advances in uveal melanoma treatment. Med Res Rev. 2017 Nov;37(6):1350-1372. (* contributed equally)

  32. Vujic I, Herman R, Sanlorenzo M, , Monshi B, Rappersberger K, Richter L. Apremilast in psoriasis - a prospective real-world study. J Eur Acad Dermatol Venereol. 2017 Sep 19

  33. Sanlorenzo M, Vujic I, Esteve-Puig R, Lai K, Vujic M, Lin K, , Dimon M, Moy A, Zekhtser M, Johnston K, Gho D, Ho W, Gajjala A, Oses Prieto J, Burlingame A, Daud A, Rappersberger K, Ortiz-Urda S. The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma. Sci Rep. accepted for publication: June 4th 2018

  34. Richtig G, Richtig M, Hoetzenecker W, Saxinger W, Lange-Asschenfeldt B, Steiner A, Strohal R, Posch C, Bauer JW, Müllegger RR, Deinlein T, Sepp N, Volc-Platzer B, Nguyen VA, Schmuth M, Hoeller C, Pregartner G, Richtig E. Knowledge and Influence of Predatory Journals in Dermatology: A Pan-Austrian Survey. Acta Derm Venereol. 2018 Sep 12.

  35. Posch C, Sanlorenzo M, Ma J, Kim ST, Zekhtser M, Ortiz-Urda S. MEK/CDK4,6 co-targeting is effective in a subset of NRAS, BRAF and 'wild type' melanomas. Oncotarget. 2018 Oct 9;9(79):34990-34995. 

  36. Feichtenschlager V, Weihsengruber F, Richter L, Vujic I, Rappersberger K, Posch C. Clinical melanoma characteristics and survival – a single-center retrospective study between 2000 and 2010. Wien Med Wochenschr. 2019 Jan 16.

  37. Algazi AP, Rotow J, Posch C, Ortiz-Urda S, Pelayo A, Munster PN, Daud A. A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600e/K mutant advanced melanoma. Pigment Cell Melanoma Res. 2019 Feb 24

  38. Coppé JP, Mori M, Pan B, Yau C, Wolf D, Ruiz-Saenz A, Brunen D, Prahallad A, Cornelissen-Steijger P, Kemper K, Posch C, Wang C, Dreyer C, Krijgsman O, Lee PRE, Chen Z, Peeper D, Moasser M, Bernards R, van 't Veer L. Mapping phospho-catalytic dependencies of therapy-resistant tumors reveals new actionable vulnerabilities. Nat Cell Biol. 2019 Jun;21(6):778-790

  39. Platzer KD, Kostner L, Vujic I, Monshi B, Richter L, Rappersberger K, Posch C. Clinical characteristics and treatment outcomes of 36 pyoderma gangrenosum patients - a retrospective, single institution observation. J Eur Acad Dermatol Venereol. 2019 Jul 16.

  40. Stary G, Posch C, Wolf P, Weninger W, Bauer JW, Schmuth M.Der zentrale Stellenwert von „Clinician-Scientists“ in der dermatologischen Forschung. J Dtsch Dermatol Ges. 2020 Jan;18(1):82-83.

  41. Monshi B, Gulz L, Piringer B, Wiala A, Kivaranovic D, Schmidt M, Sesti A, Heil T, Vujic I, Posch C, Rappersberger K. Anti BP180-autoantibody levels at diagnosis correlate with 1-year mortality rates in patients with bullous pemphigoid. J Eur Acad Dermatol Venereol. 2020 Mar 14.

  42. Amaral T, Kiecker F, Schaefer S, Stege H, Kaehler K, Terheyden P, Gesierich A, Gutzmer R, Haferkamp S, Uttikal J, Berking C, Rafei-Shamsabadi D, Reinhardt L, Meier F, Karoglan A, Posch C, Gambichler T, Pfoehler C, Thoms K, Tietze J, Debus D, Herbst R, Emmert S, Loquai C, Hassel JC, Meiss F, Tueting T, Heinrich V, Eigentler T, Garbe C, Zimmer L; *German Dermatological Cooperative Oncology Group. Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients. J Immunother Cancer. 2020 Mar;8(1).

  43. Patel A, Fraile Garcia L, Mannella V, Gammon L, Borg TM, Maffucci T, Scatolini M, Chiorino G, Vergani E, Rodolfo M, Maurichi A, Posch C, Matin RN, Harwood CA, Bergamaschi D. Targeting p63 upregulation abrogates resistance to MAPK inhibitors in melanoma. Cancer Res. 2020 Apr 14.

  44. Posch C. Journal-Club. J Dtsch Dermatol Ges. 2020 Apr;18(4):415.

  45. Schmidle P, Biedermann T, Posch C. COVID-19 in a melanoma patient under treatment with checkpoint-inhibition. J Eur Acad Dermatol Venereol. 2020 May 26:10.1111/jdv.16661. doi: 10.1111/jdv.16661. Online ahead of print.

  46. Eberlein B, Biedermann T, Hein R, Posch C. Vemurafenib-related photosensitivity. J Dtsch Dermatol Ges. 2020 Jun 18. doi: 10.1111/ddg.14140. Online ahead of print.

  47. Hoffmann F, Zarbl R, Niebel D, Sirokay J, Fröhlich A, Posch C, Holderried TAW, Brossart P, Saavedra G, Kuster P, Strieth S, Gielen GH, Ring SS, Dietrich J, Pietsch T, Flatz L, Kristiansen G, Landsberg J, Dietrich D.Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma. Clin Epigenetics. 2020 Jun 26;12(1):94. doi: 10.1186/s13148-020-00883-9.

  48. Boehmer DF, Möckel S, Eyerich K, Biedermann T, Posch C. Multiple pustular lesions in a patient with ulcerative colitis - successfully treated with TNF-alpha-inhibitor. J Dtsch Dermatol Ges. 2020 Sep 28.

  49. Wang R, Uretzki M, Boehmer D, Hein R, Biedermann T, Posch C. Severe thrombocytopenia and excellent response following combined immune checkpoint inhibition for metastatic malignant melanoma. J Eur Acad Dermatol Venereol. 2020 Jul 23.

  50. Platzer KD, Steimle-Grauer SA, Biedermann T, Posch C. A female patient with a receding hairline. J Dtsch Dermatol Ges. 2020 Jul 27.

  51. Wessely A, Steeb T, Berking C, Schlaak M, Heppt MV; Surveillance of patients with conjunctival melanoma in German-speaking countries: A multinational survey of the German dermatologic cooperative oncology group. German Dermatologic Cooperative Oncology Group.. Eur J Cancer. 2020 Dec 3;143:43-45.

  52. Steeb T, Wessely A, Alter M, Bayerl C, Bender A, Bruning G, Dabrowski E, Debus D, Devereux N, Dippel E, Drexler K, Dücker P, Dummer R, Emmert S, Elsner P, Enk A, Gebhardt C, Gesierich A, Goebeler M, Goerdt S, Goetze S, Gutzmer R, Haferkamp S, Hansel G, Hassel JC, Heinzerling L, Kähler KC, Kaume KM, Krapf W, Kreuzberg N, Lehmann P, Livingstone E, Löffler H, Loquai C, Mauch C, Mangana J, Meier F, Meissner M, Moritz RKC, Maul LV, Müller V, Mohr P, Navarini A, Van Nguyen A, Pfeiffer C, Pföhler C, Posch C, Richtig E, Rompel R, Sachse MM, Sauder S, Schadendorf D, Schatton K, Schulze HJ, Schultz E, Schilling B, Schmuth M, Simon JC, Streit M, Terheyden P, Thiem A, Tüting T, Welzel J, Weyandt G, Wesselmann U, Wollina U, Ziemer M, Zimmer L, Zutt M, Berking C, Schlaak M, Heppt MV; German Dermatologic Cooperative Oncology Group. Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG). J Cancer Res Clin Oncol. 202 Nov 21.

  53. Fietz S, Zarbl R, Niebel D, Posch C, Brossart P, Gielen GH, Strieth S, Pietsch T, Kristiansen G, Bootz F, Landsberg J, Dietrich D. CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab). Cancer Immunol Immunother. 2020 Nov 16.

  54. Rogiers A, Pires da Silva I, Bianchetti A, Tondini C, Grimes JM, Trager MH, Nahm S, Zubiri L, Manos M, Bowling P, Elkrief A, Papneja N, Vitale MG, Rose A, Borgers J, Roy S, Mangana J, Muniz T, Cooksley T, Lupu J, Saibil S, Hogg D, Butler M, Menzies A, Carlino M, Erdmann M, Berking C, Zimmer L, Schadendorf D, Conforti F, Queirolo P, Posch C, Hauschild A, Dummer R, Haanen J, Blank C, Robert C, Flaherty KT, Sullivan R, Ascierto PA, Miller W, Hodi FS, Suijkerbuijk K, Reynolds K, Rahma OE, Lorigan P, Carvajal RD, Lo S, Mandala M, Long GV. The clinical impact of COVID-19 on cancer patients treated with immune checkpoint inhibition. Accepted for publication Cancer Immunol Immunother. 11/2020

  55. Ressler J, Karasek M, Koch L, Silmbrod R, Mangana J, Sofiya L, Aedo Lopez V, Kehrer H, Weihsengruber F, Koelblinger P, Posch C, Kofler J, Michielin O, Richtig E, Hafner C, Höller C. Real Life Use of Talimogene Laherparepvec (T-VEC) in Melanoma Patients in Centers in Austria, Switzerland and Germany. Accepted for publication Cancer Immunol Immunother. 12/2020

  56. Wiala A, Vujic I, Richter L, Rappersberger K, Posch C. Dermatomyositis requires long-term treatment with combined immunosuppressive and immunoglobulin therapy. J Dtsch Dermatol Ges. 2021 Mar;19(3):456-458. doi: 10.1111/ddg.14365.

  57. Arenbergerova M, Lallas A, Nagore E, Rudnicka L, Forsea A, Pasek M, Meier F, Peris K, Olah J, Posch C. Position statement of the EADV Melanoma Task Force on recommendations for the management of cutaneous melanoma patients during COVID-19. J Eur Acad Dermatol Venereol. 2021 Mar 29. doi: 10.1111/jdv.17252. 

  58. Hoesl C, Fröhlich T, Posch C, Kneitz H, Goebeler M, Schneider MR, Dahlhoff M. The transmembrane protein LRIG1 triggers melanocytic tumor development following chemically induced skin carcinogenesis. Mol Oncol. 2021 Mar 31. doi: 10.1002/1878-0261.12945. 

  59. Kessel KA, Deichl A, Gempt J, Meyer B, Posch C, Diehl C, Zimmer C, Combs SE. Outcomes after stereotactic radiosurgery of brain metastases in patients with malignant melanoma and validation of the melanoma molGPA. Clin Transl Oncol. 2021 May 15.

bottom of page